News | January 27, 2015

Early knowledge of AKI risk may prompt closer patient monitoring and help prevent permanent kidney damage or death

Nephrocheck Test System, Blood testing, contrast media
Image courtesy of Astute Medical

January 27, 2015 — Ortho-Clinical Diagnostics Inc. announced the nationwide availability to hospitals of the Nephrocheck Test System designed to help healthcare providers identify patients at risk of developing moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment.

In comparing patients with AKI to patients without AKI, hospital and the intensive care unit lengths of stay double, as do costs of care and readmission rates.  Death rates at one year are higher among patients with AKI alone, compared to those patients with heart attack alone.

AKI usually lacks signs and symptoms and can potentially result in irreversible kidney damage if recognition is delayed. In clinical studies, the Nephrocheck Test identified the majority of patients that developed moderate to severe AKI within 12 hours of assessment.

The Nephrocheck Test result, called the AKIRisk Score, has the ability to distinguish patients with AKI from those without AKI. Based on results from clinical studies, patients with a positive AKIRisk Score (greater than the cutoff of 0.3) have a one in four to a one in three chance of developing moderate or severe AKI within 12 hours of assessment.

To calculate the AKIRisk Score, the Nephrocheck Test System measures the concentrations of two urinary biomarkers using the Astute140 Meter. The two novel biomarkers -- tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7, are thought to be involved in G1 cell cycle arrest in the earliest phases of injury.

In July 2014, Ortho-Clinical Diagnostics entered into collaboration with Astute Medical Inc., the developer of the Nephrocheck Test System, to become the exclusive sales agent for Astute Medical’s Nephrocheck Test and the Astute140 Meter in the United States and in certain countries of the European Union.

For more information: www.orthoclinical.com/en-us/Pages/Home.aspx, www.astutemedical.com

 

 

Related Content

Feature | Radiology Business | Melinda Taschetta-Millane

November 2, 2021 — Here is a list of the Top 10 most popular pieces of content on ITNonline.com from the month of ...

Time November 02, 2021
arrow
News | Ultrasound Imaging

October 5, 2021 — Ultrasound experts urged the health care community to work to expand utilization of ultrasound ...

Time October 05, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

September 20, 2021 — Gadolinium-based contrast agents, the gold standard in magnetic resonance imaging (MRI) to ...

Time September 20, 2021
arrow
News | Contrast Media Injectors

September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthcare ...

Time September 16, 2021
arrow
News | PET-CT

August 4, 2021 — PET/CT systems are expected to continue to incorporate the highest clinical performance of PET as well ...

Time August 04, 2021
arrow
News | Contrast Media

July 30, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), the resources required to warm iohexol 350 ...

Time July 30, 2021
arrow
News | Contrast Media

June 30, 2021 – IQ-AI subsidiary Imaging Biometrics (IB) was awarded a U.S. patent for its artificial intelligence (AI) ...

Time June 30, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

May 12, 2021 — According to the British Heart Foundation, heart and circulatory diseases cause more than a quarter (27 ...

Time May 12, 2021
arrow
News | Contrast Media

May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...

Time May 11, 2021
arrow
News | Contrast Media

Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or ...

Time May 03, 2021
arrow
Subscribe Now